DBD vs AGYS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

DBD

33.8
AI Score
VS
DBD Wins

AGYS

32.6
AI Score

Investment Advisor Scores

DBD

34score
Recommendation
AVOID NEW MONEY

AGYS

33score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric DBD AGYS Winner
Forward P/E 12.1655 45.6621 DBD
PEG Ratio 0 2.2807 Tie
Revenue Growth 1.7% 14.3% AGYS
Earnings Growth 34.2% 88.2% AGYS
Tradestie Score 33.8/100 32.6/100 DBD
Profit Margin 2.9% 13.0% AGYS
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

DBD 1M: +9.9% · 3M: -22.5% AGYS 1M: +18.7% · 3M: +21.8%

Current Technical Phase

DBD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 64

RSI (14): 63.6 · Price: $69.26

AGYS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 70

RSI (14): 70.2 · Price: $120.07

Fundamentals Snapshot

Metric DBD AGYS
Market Cap — —
Forward P/E 9.9 55.2
Trailing P/E 22.4 76.3
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.3% 0.6%
Operating Margin 0.1% 0.1%
EPS 3.04 1.52
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DBD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.